Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Strain- and species-specific immune responses to human adipose stem cell-derived extracellular vesicles: A comparative pharmacological evaluation in mice and human PBMCs.

Kim DO., Nguyen QT., Choi YC., Choi JS., Lee KS., Cho YW.

Animal Study on Immune Modulation, published in Eur J Pharm Biopharm (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Eur J Pharm Biopharm (2026)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
41628693
DOI
10.1016/j.ejpb.2026.115008

Abstract (original English)

Human adipose stem cell-derived extracellular vesicles (hASC-EVs) have gained attention as potential cell-free therapeutics in regenerative medicine due to their immunomodulatory properties and low immunogenicity. Despite this promise, their immunotoxicity profile remains insufficiently characterized, particularly across species and genetic backgrounds. This study systematically assessed immune responses to repeated high-dose intravenous administration of hASC-EVs in two murine strains-C57BL/6 (inbred) and ICR (outbred)-and in human peripheral blood mononuclear cells (hPBMCs) in vitro. Flow cytometry of murine blood and spleen samples revealed transient, strain-dependent shifts in immune cell populations, including neutrophils, monocytes, macrophages, B cells, and NK cells. Notably, C57BL/6 mice exhibited more pronounced fluctuations than ICR mice, reflecting the role of host genetics in EV-induced immunomodulation. In contrast, hPBMCs exposed to equivalent concentrations of hASC-EVs displayed no significant changes in cell viability, immune cell subset composition, or activation markers over a 24-hour period. While a mild, transient increase in CD86 + monocytes was observed at 6 h, this effect normalized by 12 h. These results suggest that hASC-EVs induce minimal and reversible immune responses in vivo and are immunologically inert in human immune cells under the tested condit

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansExtracellular VesiclesLeukocytes, MononuclearSpecies SpecificityMiceMice, Inbred C57BLMice, Inbred ICRAdipose TissueMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research